Clinical trial · no report yet · Phase 3

S1418

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874 ↗
Active, not recruiting
National Cancer Institute (NCI)
Focused

We haven't built an HCP commentary report on S1418 (pembrolizumab in Breast Carcinoma In Situ) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on S1418 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
YouTube	4
X threads	3
Podcasts	1

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Phase: Phase 3
Status: Active, not recruiting
Conditions: Breast Carcinoma In Situ; Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection; Laboratory Biomarker Analysis; Patient Observation; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
Arms: Arm I (observation) · Experimental
Arm II (pembrolizumab) · Experimental
Enrollment: 1,195
Primary outcomes: Invasive disease-free survival (IDFS)
Severity of fatigue
Physical function
Sponsor: National Cancer Institute (NCI)
Start: Jan 18, 2017
Primary completion: Aug 3, 2026
Results posted: No
Registry record: NCT02954874 · updated Oct 26, 2026